Evidence
Ageing Res Rev. 2024 Mar 19:102281. doi: 10.1016/j.arr.2024.102281. Online ahead of print.
ABSTRACT
Accumulation of the amyloid β (Aβ) peptide, derived from Aβ precursor protein (APP), is a trait of Down syndrome (DS), as is early development of dementia like Alzheimer’s disease (AD). Treatments for AD in DS simply do not exist. New drug therapies for AD, e.g., Lecanemab, are monoclonal antibodies designed to clear amyloid plaques composed of Aβ. The increasingly real ability to target and dispose of Aβ favors the use of these drugs in individuals with DS for AD, perhaps as earlier intervention for cognitive impairment. We present pertinent similarities between DS and AD in adult DS subjects, discuss challenges to target APP metabolites, and suggest that recently developed antibody treatments against Aβ may be worth investigating to treat AD in DS.
PMID:38513771 | DOI:10.1016/j.arr.2024.102281
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Alzheimer’s Drugs APPlication for Down syndrome?
🌐 90 Days
VR Related Evidence Matrix
- Types of memory, dementia, Alzheimer's disease, and their various pathological cascades as targets for potential pharmacological drugs
- Lecanemab Questions
- Sonic Hedgehog Signalling Pathway Contributes in Age-Related Disorders and Alzheimer's Disease
- The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials
- Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia
- Passive immunotherapy for Alzheimer's disease: challenges & future directions
- Is Alzheimer disease a disease?
- Hepatopancreatic metabolic disorders and their implications in the development of Alzheimer's disease and vascular dementia
- Accumulation of neutral lipids in dystrophic neurites surrounding amyloid plaques in Alzheimer's disease
- Lewy body pathology modifies risk factors for cerebral amyloid angiopathy when comorbid with Alzheimer's disease pathology
- Role of ketogenic diet in neurodegenerative diseases focusing on Alzheimer diseases: The guardian angle
- Role of ketogenic diet in neurodegenerative diseases focusing on Alzheimer diseases: The guardian angle
- Using Drosophila amyloid toxicity models to study Alzheimer's disease
- Divergent Age-Dependent Conformational Rearrangement within Ab Amyloid Deposits in APP23, APPPS1, and AppNL-F Mice
- Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study
- Disease-Modifying Treatments and Their Future in Alzheimer's Disease Management
- Generating PET scan patterns in Alzheimer's by a mathematical model
- Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient
- Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease
- CSF protein ratios with enhanced potential to reflect Alzheimer's disease pathology and neurodegeneration
- Alpha-, Beta-, and Gamma-Secretase, Amyloid Precursor Protein, and Tau Protein Genes in the Hippocampal CA3 Subfield in an Ischemic Model of Alzheimer's Disease with Survival up to 2 Years
- PPARs (Peroxisome Proliferator-activated Receptors) and Their Agonists in Alzheimer's Disease
- Mechanisms of pain in aging and age-related conditions: focus on caregivers
- Vascular Dementia: From Pathobiology to Emerging Perspectives
- Insights into amyloid precursor protein target through PPI network analysis
- Clinical Arterial Spin-Labeling MR Imaging to Screen for Typical and Atypical Neurodegenerative Disease in the New Era of Alzheimer Treatment
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- Multiple system atrophy with amyloid-b-predominant Alzheimer's disease neuropathologic change
- NLRP3 inflammasome signalling in Alzheimer's disease
- The efficacy of dyadic interventions for community-dwelling people with dementia and their caregivers: a systematic review and meta-analysis
- Exploring the potential of quercetin in Alzheimer's Disease: Pharmacodynamics, Pharmacokinetics, and Nanodelivery systems
- Bacteroidota inhibit microglia clearance of amyloid-beta and promote plaque deposition in Alzheimer's disease mouse models
- In vitro and in silico investigation of FDA-approved drugs to be repurposed against Alzheimer's disease
- Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease
- Genomic stress and impaired DNA repair in Alzheimer disease
- Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease
- Role of GABAB receptors in cognition and EEG activity in aged APP and PS1 transgenic mice
- Systemic inflammation in Ab1-40-induced Alzheimer's disease model: New translational opportunities
- Kai-Xin-San ameliorates Alzheimer's disease-related neuropathology and cognitive impairment in APP/PS1 mice via the mitochondrial autophagy-NLRP3 inflammasome pathway
- D-peptide-magnetic nanoparticles fragment tau fibrils and rescue behavioral deficits in a mouse model of Alzheimer's disease
- Quantitative Brain Amyloid PET
- Brain structural indicators of beta-amyloid neuropathology
- 9-cis beta-carotene-enriched diet significantly improved cognition and decreased Alzheimer's disease neuropathology and neuroinflammation in Alzheimer's disease-like mouse models
- 9-cis beta-carotene-enriched diet significantly improved cognition and decreased Alzheimer's disease neuropathology and neuroinflammation in Alzheimer's disease-like mouse models
- Lecanemab blocks the effects of the Ab/fibrinogen complex on blood clots and synapse toxicity in organotypic culture
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
- Preliminary study on early diagnosis of Alzheimer's disease in APP/PS1 transgenic mice using multimodal magnetic resonance imaging
- Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease
- Understanding age-related pathologic changes in TDP-43 functions and their consequence on RNA splicing and signalling in health and disease
- Present and future of Blood-Based biomarkers of Alzheimer's Disease: Beyond the classics
- Proton Pump Inhibitors and Cognitive Health: Review on Unraveling the Dementia Connection and Co-morbid Risks
- β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer's disease
- Tau-PET in early cortical Alzheimer brain regions in relation to mild behavioral impairment in older adults with either normal cognition or mild cognitive impairment
- Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias
- Peptide-derived ligands for the discovery of safer opioid analgesics
- Predicting Progression From Mild Cognitive Impairment to Alzheimer's Dementia With Adversarial Attacks
- Recent Advances in Fluorescent Theranostics for Alzheimer's Disease: A Comprehensive Survey on Design, Synthesis, and Properties
- Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial
- Predicting functional decline in aging and Alzheimer's disease with PET-based Braak staging
- A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Bioactive Peptides
- Advances in nanoprobes for molecular MRI of Alzheimer's disease
- Minimal clinically important difference in Alzheimer's disease: Rapid review
- Alzheimer's Disease Diagnosis in the Preclinical Stage: Normal Aging or Dementia
Evidence Blueprint
Alzheimer’s Drugs APPlication for Down syndrome?
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Alzheimer’s Drugs APPlication for Down syndrome?
🌐 365 Days
VR Related Evidence Matrix
- How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?
- Types of memory, dementia, Alzheimer's disease, and their various pathological cascades as targets for potential pharmacological drugs
- Once upon a time, the Amyloid Cascade Hypothesis
- Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: a systematic review and network meta-analysis
- GLP-1/Sigma/RAGE Receptors: An evolving picture of Alzheimer's Disease pathology and treatment
- Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK
- Anti-amyloid antibody treatments for Alzheimer's disease
- Understanding the mechanisms of disease modifying effects of aerobic exercise in people with Alzheimer's disease
- Navigating the Dementia Landscape: Biomarkers and Emerging Therapies
- Psychedelics for Alzheimer's Disease-Related Dementia: Unveiling Therapeutic Possibilities and Pathways
- Ischemia-Reperfusion Programming of Alzheimer's Disease-Related Genes-A New Perspective on Brain Neurodegeneration after Cardiac Arrest
- Lecanemab Questions
- Sonic Hedgehog Signalling Pathway Contributes in Age-Related Disorders and Alzheimer's Disease
- The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials
- Passive tau-based immunotherapy for tauopathies
- Fe65-engineered neuronal exosomes encapsulating corynoxine-B ameliorate cognition and pathology of Alzheimer's disease
- Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia
- Passive immunotherapy for Alzheimer's disease: challenges & future directions
- Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis
- Recent Advancement in Therapeutic Strategies for Alzheimer's Disease: Insights from Clinical Trials
- Is Alzheimer disease a disease?
- Cost-effectiveness comparison between blood biomarkers and conventional tests in Alzheimer's disease diagnosis
- Alzheimer's Disease: The Past, Present, and Future of a Globally Progressive Disease
- New horizons in the diagnosis and management of Alzheimer's Disease in older adults
- Myelin dysfunction drives amyloid-β deposition in models of Alzheimer's disease
- Human iPSC-derived retinal organoids develop robust Alzheimer's disease neuropathology
- Hepatopancreatic metabolic disorders and their implications in the development of Alzheimer's disease and vascular dementia
- Accumulation of neutral lipids in dystrophic neurites surrounding amyloid plaques in Alzheimer's disease
- Lewy body pathology modifies risk factors for cerebral amyloid angiopathy when comorbid with Alzheimer's disease pathology
- Role of ketogenic diet in neurodegenerative diseases focusing on Alzheimer diseases: The guardian angle
- Role of ketogenic diet in neurodegenerative diseases focusing on Alzheimer diseases: The guardian angle
- Using Drosophila amyloid toxicity models to study Alzheimer's disease
- Targeted examination of amyloid beta and tau protein accumulation via positron emission tomography for the differential diagnosis of Alzheimer's disease based on the A/T(N) research framework
- Amyloid precursor protein facilitates SARS-CoV-2 virus entry into cells and enhances amyloid-β-associated pathology in APP/PS1 mouse model of Alzheimer's disease
- Divergent Age-Dependent Conformational Rearrangement within Ab Amyloid Deposits in APP23, APPPS1, and AppNL-F Mice
- Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study
- Disease-Modifying Treatments and Their Future in Alzheimer's Disease Management
- The link between Alzheimer disease and metabolic syndrome: A mutual relationship and long rigorous investigation
- Lecanemab: Appropriate Use Recommendations
- Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs
- O-GalNAc glycosylation determines intracellular trafficking of APP and Aβ production
- Generating PET scan patterns in Alzheimer's by a mathematical model
- Early onset diagnosis in Alzheimer's disease patients via amyloid-β oligomers-sensing probe in cerebrospinal fluid
- Hydrodynamic Control of Alzheimer Aβ Fibrillation with Glucosaminic Acid Containing Click-Cyclized β-Bodies
- Longitudinal changes in hippocampal texture from healthy aging to Alzheimer's disease
- Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology
- Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient
- Utility of amyloid PET Imaging in a Memory Clinic
- ArhGAP11A mediates amyloid-β generation and neuropathology in an Alzheimer's disease-like mouse model
- Apolipoprotein E Genetic Testing in a New Age of Alzheimer Disease Clinical Practice
- Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease
- CSF protein ratios with enhanced potential to reflect Alzheimer's disease pathology and neurodegeneration
- Detection of β-amyloid aggregates/plaques in 5xFAD mice by labelled native PLGA nanoparticles: implication in the diagnosis of alzheimer's disease
- γ-Secretase Inhibitors Selected by Molecular Docking, to Develop a New Drug Against Alzheimer's Disease
- Trial of Solanezumab in Preclinical Alzheimer's Disease
- Aβ1-6A2V(D) peptide, effective on Aβ aggregation, inhibits tau misfolding and protects the brain after traumatic brain injury
- Alpha-, Beta-, and Gamma-Secretase, Amyloid Precursor Protein, and Tau Protein Genes in the Hippocampal CA3 Subfield in an Ischemic Model of Alzheimer's Disease with Survival up to 2 Years
- PPARs (Peroxisome Proliferator-activated Receptors) and Their Agonists in Alzheimer's Disease
- Alzheimer risk-increasing TREM2 variant causes aberrant cortical synapse density and promotes network hyperexcitability in mouse models
- Alzheimer's Disease and Alzheimer's Disease-Related Dementias in Hispanics: Identifying Influential Factors and Supporting Caregivers
- Mechanisms of pain in aging and age-related conditions: focus on caregivers
- Peripheral blood amyloid-β involved in the pathogenesis of Alzheimer's disease via impacting on peripheral innate immune cells
- Cancer drugs with high repositioning potential for Alzheimer's disease
- How donanemab data address the coverage with evidence development questions